# Lorundrostat

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/lorundrostat
Canonical HTML page: https://getyourbrief.com/entity/lorundrostat

## Timeline

- **2026-03-12**: Q4 2025 Earnings — Both Mineralys and Vuzix report year-end financial results and 2026 guidance.
- **2026-03-09**: FDA NDA Acceptance — FDA formally accepts Mineralys Therapeutics' application for Lorundrostat.
- **2026**: PDUFA Goal Date — Expected timeframe for the FDA's final decision on Lorundrostat commercialization.

## Recent coverage (3 stories, network-wide)

### Mineralys and Vuzix Q4 Earnings: Biotech Milestones vs. AR Scaling
2026-03-12 23:34:01 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Mineralys Therapeutics secured a major regulatory win with FDA acceptance of its Lorundrostat NDA, while Vuzix continues to navigate the transition from pilot programs to enterprise-scale AR deployments.
Full story: https://getfinancebrief.com/story/mineralys-vuzix-q4-2025-earnings-analysis

### Mineralys Therapeutics Advances Lorundrostat NDA Amid Q4 Earnings Beat
2026-03-12 23:33:25 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Mineralys Therapeutics (MLYS) reported a narrower-than-expected Q4 2025 loss and confirmed the FDA's acceptance of its New Drug Application for lorundrostat. The company is now pivoting toward commercial readiness for its lead hypertension candidate while maintaining a robust clinical pipeline in chronic kidney disease.
Full story: https://getbiobrief.com/story/mineralys-mlys-q4-2025-earnings-lorundrostat-nda

### Mineralys and Vuzix Q4 2025: Clinical Milestones and AR Adoption in Focus
2026-03-12 23:32:16 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Mineralys (MLYS) and Vuzix (VUZI) reported Q4 2025 results, highlighting divergent but critical paths in healthcare innovation: the clinical validation of next-generation hypertension therapies and the operational scaling of augmented reality in surgical settings. While Mineralys focuses on pivotal trial readouts for lorundrostat, Vuzix is navigating a transition toward OEM and high-margin medical software solutions.
Full story: https://gethealthbrief.com/story/mineralys-vuzix-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.